Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2026-01-27

FDA Approved: PRIFTIN — Supplemental Application (sanofi-aventis U.S. LLC)

View source ↗

Summary

The FDA approved a supplemental application for PRIFTIN (rifapentine) from Sanofi-Aventis U.S. LLC.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Priftin (rifapentine)

Snippet

SUPPL AP for PRIFTIN (RIFAPENTINE)